S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
CVE:LXG

LexaGene Stock Forecast, Price & News

C$0.28
-0.03 (-8.20%)
(As of 01/21/2022 03:59 PM ET)
Add
Compare
Today's Range
C$0.27
C$0.29
50-Day Range
C$0.28
C$0.56
52-Week Range
C$0.26
C$1.54
Volume
17,510 shs
Average Volume
52,809 shs
Market Capitalization
C$33.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive LXG News and Ratings via Email

Sign-up to receive the latest news and ratings for LexaGene and its competitors with MarketBeat's FREE daily newsletter.


LexaGene logo

About LexaGene

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.

Headlines

LexaGene (CVE:LXG) Shares Down 8.2%
January 22, 2022 |  americanbankingnews.com
LexaGene Closes Multiple MiQLab Sales - GlobeNewswire
December 3, 2021 |  globenewswire.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Sales & Book Value

Annual Sales
C$98.75 thousand
Cash Flow
C$0.03 per share
Book Value
C$0.05 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
C$33.35 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












LexaGene (CVE:LXG) Frequently Asked Questions

How has LexaGene's stock been impacted by COVID-19 (Coronavirus)?

LexaGene's stock was trading at C$0.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LXG shares have decreased by 61.6% and is now trading at C$0.28.
View which stocks have been most impacted by COVID-19
.

Who are LexaGene's key executives?

LexaGene's management team includes the following people:
  • Dr. John F. Regan, Founder, Chairman & CEO
  • Mr. Jeffrey Mitchell, CFO, Treasurer & Corp. Sec.
  • Mr. Steven Armstrong, Chief Operating Officer
  • Mr. Allan John Fabbro, VP of Corp. Devel. (Age 64)
  • Nicole Ridgedale, Director of Corp. Marketing
  • Jay Adelaar, VP of Capital Markets

What other stocks do shareholders of LexaGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LexaGene investors own include Jaguar Mining (JAG), Northern Superior Resources (SUP), Vaccinex (VCNX), Gevo (GEVO), HIVE Blockchain Technologies (HIVE), (CVLB), EQT (EQT), Freehold Royalties (FRU), GFG Resources (GFG) and IAMGOLD (IMG).

What is LexaGene's stock symbol?

LexaGene trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LXG."

How do I buy shares of LexaGene?

Shares of LXG and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is LexaGene's stock price today?

One share of LXG stock can currently be purchased for approximately C$0.28.

How much money does LexaGene make?

LexaGene has a market capitalization of C$33.35 million and generates C$98.75 thousand in revenue each year.

How many employees does LexaGene have?

LexaGene employs 34 workers across the globe.

What is LexaGene's official website?

The official website for LexaGene is www.lexagene.com.

How can I contact LexaGene?

The company can be reached via phone at 800-215-1824.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.